Cargando…

Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma

Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation. Functional evidence shows that the BLU gene inhibits tumor growth in animal assays, but the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Y, Ho, R L K Y, Chan, K C, Kan, R, Tung, E, Lung, H L, Yau, W L, Cheung, A K L, Ko, J M Y, Zhang, Z F, Luo, D Z, Feng, Z B, Chen, S, Guan, X Y, Kwong, D, Stanbridge, E J, Lung, M L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761643/
https://www.ncbi.nlm.nih.gov/pubmed/25347745
http://dx.doi.org/10.1038/onc.2014.353
_version_ 1782416989231251456
author Cheng, Y
Ho, R L K Y
Chan, K C
Kan, R
Tung, E
Lung, H L
Yau, W L
Cheung, A K L
Ko, J M Y
Zhang, Z F
Luo, D Z
Feng, Z B
Chen, S
Guan, X Y
Kwong, D
Stanbridge, E J
Lung, M L
author_facet Cheng, Y
Ho, R L K Y
Chan, K C
Kan, R
Tung, E
Lung, H L
Yau, W L
Cheung, A K L
Ko, J M Y
Zhang, Z F
Luo, D Z
Feng, Z B
Chen, S
Guan, X Y
Kwong, D
Stanbridge, E J
Lung, M L
author_sort Cheng, Y
collection PubMed
description Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation. Functional evidence shows that the BLU gene inhibits tumor growth in animal assays, but the detailed molecular mechanism responsible for this is still not well understood. In current studies, we find that 93.5% of early-stage primary NPC tumors show downregulated BLU expression. Using a PCR array, overexpression of the BLU gene was correlated to the angiogenesis network in NPC cells. Moreover, expression changes of the MMP family, VEGF and TSP1, were often detected in different stages of NPC, suggesting the possibility that BLU may be directly involved in the microenvironment and anti-angiogenic activity in NPC development. Compared with vector-alone control cells, BLU stable transfectants, derived from poorly-differentiated NPC HONE1 cells, suppress VEGF165, VEGF189 and TSP1 expression at both the RNA and protein levels, and significantly reduce the secreted VEGF protein in these cells, reflecting an unknown regulatory mechanism mediated by the BLU gene in NPC. Cells expressing BLU inhibited cellular invasion, migration and tube formation. These in vitro results were further confirmed by in vivo tumor suppression and a matrigel plug angiogenesis assay in nude mice. Tube-forming ability was clearly inhibited, when the BLU gene is expressed in these cells. Up to 70–90% of injected tumor cells expressing increased exogenous BLU underwent cell death in animal assays. Overexpressed BLU only inhibited VEGF165 expression in differentiated squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a complicated mechanism regulating angiogenesis and the microenvironment in different NPC cell lines. Results of these studies indicate that alteration of BLU gene expression influences anti-angiogenesis pathways and is important for the development of NPC.
format Online
Article
Text
id pubmed-4761643
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47616432016-03-04 Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma Cheng, Y Ho, R L K Y Chan, K C Kan, R Tung, E Lung, H L Yau, W L Cheung, A K L Ko, J M Y Zhang, Z F Luo, D Z Feng, Z B Chen, S Guan, X Y Kwong, D Stanbridge, E J Lung, M L Oncogene Original Article Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation. Functional evidence shows that the BLU gene inhibits tumor growth in animal assays, but the detailed molecular mechanism responsible for this is still not well understood. In current studies, we find that 93.5% of early-stage primary NPC tumors show downregulated BLU expression. Using a PCR array, overexpression of the BLU gene was correlated to the angiogenesis network in NPC cells. Moreover, expression changes of the MMP family, VEGF and TSP1, were often detected in different stages of NPC, suggesting the possibility that BLU may be directly involved in the microenvironment and anti-angiogenic activity in NPC development. Compared with vector-alone control cells, BLU stable transfectants, derived from poorly-differentiated NPC HONE1 cells, suppress VEGF165, VEGF189 and TSP1 expression at both the RNA and protein levels, and significantly reduce the secreted VEGF protein in these cells, reflecting an unknown regulatory mechanism mediated by the BLU gene in NPC. Cells expressing BLU inhibited cellular invasion, migration and tube formation. These in vitro results were further confirmed by in vivo tumor suppression and a matrigel plug angiogenesis assay in nude mice. Tube-forming ability was clearly inhibited, when the BLU gene is expressed in these cells. Up to 70–90% of injected tumor cells expressing increased exogenous BLU underwent cell death in animal assays. Overexpressed BLU only inhibited VEGF165 expression in differentiated squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a complicated mechanism regulating angiogenesis and the microenvironment in different NPC cell lines. Results of these studies indicate that alteration of BLU gene expression influences anti-angiogenesis pathways and is important for the development of NPC. Nature Publishing Group 2015-08-06 2014-10-27 /pmc/articles/PMC4761643/ /pubmed/25347745 http://dx.doi.org/10.1038/onc.2014.353 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Article
Cheng, Y
Ho, R L K Y
Chan, K C
Kan, R
Tung, E
Lung, H L
Yau, W L
Cheung, A K L
Ko, J M Y
Zhang, Z F
Luo, D Z
Feng, Z B
Chen, S
Guan, X Y
Kwong, D
Stanbridge, E J
Lung, M L
Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title_full Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title_fullStr Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title_full_unstemmed Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title_short Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma
title_sort anti-angiogenic pathway associations of the 3p21.3 mapped blu gene in nasopharyngeal carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761643/
https://www.ncbi.nlm.nih.gov/pubmed/25347745
http://dx.doi.org/10.1038/onc.2014.353
work_keys_str_mv AT chengy antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT horlky antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT chankc antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT kanr antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT tunge antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT lunghl antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT yauwl antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT cheungakl antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT kojmy antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT zhangzf antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT luodz antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT fengzb antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT chens antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT guanxy antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT kwongd antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT stanbridgeej antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma
AT lungml antiangiogenicpathwayassociationsofthe3p213mappedblugeneinnasopharyngealcarcinoma